U.S. DOD CDMRP – Breast cancer research program

Through the Congressionally Directed Medical Research Program (CDMRP), the Department of Defense is announcing the breast Cancer Research Program (KCRP) Awards. Five award programs are available:
 

• The FY22 innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. The Innovator Award will provide these individuals with the funding and freedom to pursue their most novel, visionary, high-risk ideas that could accelerate progress to ending breast cancer. Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of their full-time effort during the award period to breast cancer research. Because the intent of the Innovator Award mechanism is to recognize these remarkably creative and innovative visionary individuals, rather than projects, the central feature of the award is the innovative contribution that the Principal Investigator (PI) can make toward ending breast cancer.
• FY22 Breakthrough Award - Levels 1 and 2 – supports promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:
  • Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer.
  • Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application.
    • Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem. To foster research that yields new avenues of investigation, preliminary data are not required. Proof of concept is the anticipated outcome.
    • Funding Level 2: Research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the breast cancer landscape.
• FY22 Breakthrough Award - Level 3 -  Advanced translational studies with a high degree of project readiness. Where relevant, proof of availability of and access to necessary data, human samples, cohort(s) and/or critical reagents must be provided.
• FY22 Breakthrough Award - Level 4 - Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Human clinical trials are required. PIs are expected to have experience in successfully leading large-scale projects and demonstrated ability (through personal experience or via a commitment from a collaborating clinical investigator) to implement a clinical project successfully..
• FY22 Breast Cancer Research Program -- Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. These individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, innovation, and productivity. They should have demonstrated experience in forming effective partnerships and collaborations and must exhibit strong potential for future leadership in breast cancer research.

• Prevent breast cancer (primary prevention)
• Identify determinants of breast cancer initiation, risk, or susceptibility
• Distinguish deadly from non-deadly breast cancers
• Conquer the problems of overdiagnosis and overtreatment
• Identify what drives breast cancer growth; determine how to stop it
• Identify why some breast cancers become metastatic
• Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
• Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
• Eliminate the mortality associated with metastatic breast cancer.

• FY22 Innovator Award - Pre-Application (1 page limit): Aug. 3, 2022, submission on Nov. 2, 2022
• FY22 Breakthrough Award -- Levels 1 and 2 - Pre-Application (1 page limit): Sept. 22, 2022, submission on Oct. 6, 2022
• FY22 Breakthrough Award -- Level 3 - Pre-Application: Aug. 3, 2022, submission on Nov. 2, 2022
• FY22 Breakthrough Award -- Level 4 - Pre-Application: Aug. 3, 2022, submission on Nov. 2, 2022
• FY22 Breast Cancer Research Program -- Era of Hope Scholar Award- Pre-Application: Sept. 22, 2022, submission on Oct 6, 2022

• FY22 Innovator Award - Anticipated direct costs will not exceed $7M for a maximum of 4 year period of performance
• FY22 Breakthrough Award -- Levels 1 and 2 - Anticipated direct costs will not exceed $450,000 for a maximum of 3 years period of performance for funding level 1/single PI, $750,000 for 3 years period of performance for funding level 1/partnering PI, $1M for 3 years for funding level 2/single PI and $1.5M for 4 years for funding level 2/partnering PI
• FY22 Breakthrough Award -- Level 3 - Anticipated direct costs will not exceed $4M for a maximum of 4 years period of performance for a single PI, $5M for 4 years with partnering PI option.
• FY22 Breakthrough Award - Level 4 - Anticipated direct costs will not exceed $10M for a maximum of 4 years period of performance.
• FY22 Breast Cancer Research Program -- Era of Hope Scholar Award - Anticipated direct costs will not exceed $3M for a maximum of 4 years period of performance.

• FY22 Innovator Award - W81XWH-22-BCRP-INNOV-2
• FY22 Breakthrough Award - Levels 1 and 2 - W81XWH-22-BCRP-BTA12-2
• FY22 Breakthrough Award - Levels 3 - W81XWH-22-BCRP-BTA3-2
• FY22 Breakthrough Award - Levels 4 - W81XWH-22-BCRP-BTA4-2
• FY22 Breast Cancer Research Program - Era of Hope Scholar Award - W81XWH-22-BCRP-EOHS-2